Alopecia Market Size, Share & Trends Analysis Report By Disease Type (Alopecia Areata, Cicatricial, Traction, Androgenetic Alopecia), By Treatment, By Gender, By Sales Channel, By End-use, By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global alopecia market size was valued at USD 8.2 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 9.0% from 2023 to 2030. One of the major growth driving factors for the market is the increasing awareness of alopecia, as people are becoming more conscious of their appearance and actively seeking solutions to address hair loss. The increasing prevalence of hair loss, technological advancements in alopecia treatment, and the rise in the prevalence of chronic diseases that are associated with hair loss are some of the major factors driving the market growth globally.

According to data published by the American Hair Loss Association, it was stated that over 95% of hair loss in men is caused due to androgenetic alopecia. Similarly, data published by the International Society of Hair Restoration Surgery, it was estimated that nearly 40% of men encounter some degree of hair loss by 35 years of age, 65% at 60 years, 70% at 80 years, and 80% at the age of 85.

The growing prevalence of hair loss is one of the major factors driving market growth. According to the American Academy of Dermatology Association (AAD), about 50 million men and 30 million women were estimated to be affected by some form of alopecia in the U.S. in 2018. According to data published by the Journal of Clinical and Diagnostic Research (JCDR), around 60% of the population has hair thinning problems and pattern hair loss is the most common form of hair loss in both males and females. Moreover, around 2% of the population is at risk of developing AA in their lifetime globally, irrespective of gender.

The global rise in healthcare expenditure is also a major factor driving the industry’s growth. Major countries in North America, Asia Pacific, Latin America, and Europe are witnessing a significant increase in per capita healthcare expenditure. According to the National Expenditure Projection 2014-2024, healthcare expenditure in the U.S. is expected to grow at an average rate of 5.8% per year. Healthcare expenditure accounted for 17.4% of GDP in 2013 and is expected to grow to 19.6% by 2024. The U.S. government has made significantly high healthcare expenditure over time, which was reported to be 17.04%, 17.00%, 16.88%, and 16.96% of the GDP in 2016, 2017, 2018, and 2019, respectively.

Key factors responsible for the increase in healthcare expenditure include increasing consumer disposable income and growing emphasis on aesthetic appearance. Furthermore, according to the OECD data, healthcare expenditure is increasing in developed as well as developing countries, which may help bridge the infrastructure gap in addressing the unmet medical needs of the population.

An increase in the number of initiatives undertaken by organizations, such as the National Alopecia Areata Foundation and the American Hair Loss Association, for spreading awareness about hair regrowth and available treatment options are leading to an increase in healthcare expenditure. The Affordable Care Act of 2010 provides people with affordable access to healthcare insurance, thus providing benefits to economically weaker patients. This results in an overall increase in the treatment rate, which is expected to fuel the market’s growth. Furthermore, increasing awareness regarding hair loss is increasing the demand for painless therapy with minimal side effects is fueling the treatment rate globally.

Disease Type Insights

Alopecia areata held the largest market share of 34.31% in 2022, driven by high disease prevalence and growing consumer awareness among patients. According to National Alopecia Areata Foundation, around 147 million people are affected by AA globally, out of this, around 6.8 million people live in the U.S. only. The segment is anticipated to grow at a significant growth rate over the forecast period owing to the rise in the development of novel therapy and favorable initiatives in the approval process. For instance, in March 2020, Baricitinib received the Breakthrough Therapy Designation from the U.S. FDA for the treatment of Alopecia Areata (AA). Subsequently, in June 2022, the U.S. FDA approved Olumiant (baricitinib) oral tablets as a treatment for severe AA in adult patients.

Androgenetic alopecia held the second largest market share of 31.11% in 2022. The rising awareness about these conditions, driven by proactive initiatives by organizations such as American Hair Loss Association, Alopecia World and National Hair Loss Awareness Month by HairMax (Lexington International) are contributing to the market growth. Moreover, the adoption of laser-based treatment options for AGA is also fueling market growth over the forecast period. Companies such as LUTRONIC, iRestore Hair Growth System (Freedom Laser Therapy), Lexington Intl., LLC. (HairMax) are proving innovative and painless treatment options for treating AGA.

Alopecia totalis and alopecia universalis segments are anticipated to grow at the fastest growth rate over the forecast period. Increasing awareness regarding severe forms of alopecia and an increase in research activities to develop novel and effective treatment options is expected to drive the market growth over the forecast period. According to the Genetic and Rare Diseases Information Center (GARD), around 7% to 25% of people suffering from AA develop alopecia totalis and alopecia universalis. Moreover, the presence of pipeline drugs such as baricitinib, deuruxolitinib, and ritlecitinib for the treatment of severe conditions of AA is expected to propel the segment growth over the forecast period.

Treatment Insights

The pharmaceutical segment dominates the global market with a revenue share of more than 98% in 2022. This dominance is primarily attributed to the affordability of pharmaceutical products and the high usage of prescription and OTC drugs. Finasteride and minoxidil are the most common drugs used to treat any form of alopecia. Finasteride and minoxidil are the only U.S.-approved drugs for the treatment of both Female Pattern Hair Loss (FPHL) and as well as Male Pattern Hair Loss (MPHL). Moreover, major pharmaceutical companies such as Lilly, Pfizer Inc., and Concert Pharmaceuticals are actively involved in the development of novel drugs to treat alopecia, which is anticipated to drive market growth over the forecast period.

Devices consist of laser-based devices used for hair regrowth are expected to grow at the fastest growth rate during the forecast period. Increasing adoption of painless treatment coupled with minimal side effects and adoption of home-used laser devices are forces driving the segment growth in the next 5 to 8 years. Low-level laser therapy offers the convenience of at-home use and minimizes the need for clinical visits. Moreover, it provides a non-pharmacological and non-surgical viable therapeutic action for hair restoration due to which the market is expected to grow steadily over the forecast period. FDA clearance for low-level laser therapy devices, such as iRestore and Hairmax, for the treatment of the most commonly occurring forms of alopecia, such as androgenetic alopecia, is likely to boost the market growth for the same over the forecast period.

End-use Insights

The end-use market for alopecia is currently dominated by dermatology clinics with a share of 56.87% and is also expected to grow strongly over the forecast period. Modern treatment methods such as laser technology, a strong product pipeline, and heightened consumer awareness regarding the use of prescription medicines are the main factors responsible for the continued growth of the segment. Given the consulting dermatologist’s ability to provide appropriate customized medications or therapy that yield effective results, they are often considered the preferred option for the treatment of alopecia.

The home care setting segment will be the fastest-growing segment over the forecast period owing to convenience, ease of usage, and patient comfort. Moreover, there are a growing number of regulatory approvals being given for home-use devices in addition to the growing adoption of non-invasive procedures such as laser therapy that does not require any lifestyle changes. For instance, in March 2020, the U.S. FDA approved LifeMD’s Shapiro MD hair restoration device to promote hair growth in men & women with androgenetic alopecia and available through direct-to-consumer platform & telemedicine.

Gender Insights

The male alopecia segment dominated the market in 2022 with a share of 54.72%, owing to the high prevalence of hair loss in the male population worldwide. Androgenetic alopecia is the most common alopecia in the male population. It is estimated that approximately 50 percent of men experience some degree of hair loss at an average age of 50 with over 95% of cases being the androgenetic type. Moreover, factors such as the increased amount of tobacco intake in men and a rising geriatric population, are expected to further propel the market over the forecast period.

However, the female alopecia market is anticipated to grow at the fastest rate over the forecast period. Rising awareness levels, lifestyle changes, increased PCOS levels, and a growing trend of cosmetic procedures are expected to increase the growth of the market.

Sales Channel Insights

The sales channel for the alopecia market is currently dominated by the prescription segment with a share of 66.2% due to the high number of visits to dermatologists for hair loss treatment. According to the National Library of Medicine, around 2.6 million outpatients visit dermatologists for alopecia areata treatment in the U.S. annually. Moreover, a strong product pipeline, growing disposable incomes, and rising prevalence of chronic diseases which ultimately leads to hair loss are expected to drive the segment growth at the fastest rate over the forecast period.

Whereas, the market is being further driven by the OTC segment which is widely used in the developing regions where players find multiple opportunities to address unmet medical needs of a large patient pool across countries such as China, Japan, Mexico, Brazil, and India. Moreover, OTC drugs remain the preferred choice of medication amongst males suffering from androgenetic alopecia and other types of hair loss conditions where there is a lack of approved drugs, leading consumers to rely on off-label or OTC drugs.

Regional Insights

North America commanded the regional shares in alopecia treatment in 2022 with a share of 35.89%, driven by a high prevalence of the disease, increased awareness among consumers, proactive measures taken by the government, improvements in healthcare infrastructure, and advancements in technology. In addition, the rising adoption of laser-based therapy for treating alopecia has contributed to an increase in the treatment rate in North America. Moreover, the presence of government and non-profit organizations such as the National Alopecia Areata Foundation (NAAF), Canadian Alopecia Areata Foundation, and others provide guidelines and create awareness among people, which is likely to have a positive impact on the market.

Asia Pacific is estimated to grow at the highest CAGR of over 9.5% during the forecast period. There has been an increase in the prevalence of alopecia in several Asian countries, driving the demand for effective treatment options. Rising awareness about hair loss and its impact on quality of life has also contributed to the growth of the market. Additionally, the increasing disposable income and changing lifestyles of the population have led to a higher willingness to spend on hair loss treatments.

Moreover, improving the healthcare regulatory scenario in developing countries is expected to attract international players to invest and capitalize on the available market opportunities. For instance, in 2016, China’s regulatory authority, China Food and Drug Administration approved the iGrow laser system by Apira Science, and became the first-ever laser-based hair growth device to be approved in China.

Europe is also anticipated to command a significant market share during the forecast period. This growth can be attributed to several factors, such as technological advancements and awareness campaigns organized by public & private groups. The European Hair Research Society plays an important role in conducting campaigns related to hair loss research and awareness related to effective treatment to prevent hair loss.

Key Companies & Market Share Insights

Some of the key players that dominated the global pharmaceutical market for alopecia in 2022 include Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Cipla Limited; Sun Pharmaceuticals Industries Ltd; Dr. Reddy’s Laboratories Ltd; GlaxoSmithKline plc; Aurobindo Pharma; and Mylan N.V. (Viatris Inc.).Market players are focusing on various growth strategies such as new product launches, partnerships & collaborations, expansions, and mergers & acquisitions. For instance, in May 2023, Kintor Pharmaceuticals completed a Phase II clinical trial of KX-826 in males with androgenetic alopecia. Some prominent players in the global alopecia market include:

• Johnson & Johnson Services, Inc

• Merck & Co., Inc.

• Cipla Limited

• Sun Pharmaceuticals Industries Ltd

• Dr. Reddy's Laboratories Ltd

• GlaxoSmithKline plc.; Aurobindo Pharma

• Viatris Inc.

• Pfizer, Inc.

• Lilly

• Lexington Intl., LLC (Devices)

• Freedom Laser Therapy (iRestore ID-520 helmet)

• Curallux, LLC.

• Apira Science Inc. (iGROW Laser)

• Revian Inc.

• Theradome

• Lutronic

Recent Developments

• In March 2023, Sun Pharmaceuticals Industries Ltd., a global pharmaceutical company, declared a phase 3 clinical trial data presentation for analyzing deuruxolitinib, an oral medicine to help in improving the scalp hair regrowth in patients with alopecia areata

• In June 2023, Pfizer Inc., a multinational biotechnology and pharmaceutical company, notified that the US Food and Administration (FDA) approved LITFULO^TM (ritlecitinib), an oral treatment for 12 years and above individuals with severe alopecia areata. This approval resulted in making LITFULO^TM an advanced treatment for people with alopecia areata

• In June 2022, Eli Lilly and Company, and Incyte declared the approval of OLUMIANT, a daily pill for systematically treating alopecia areata among adults, by the US Food and Administration (FDA). Patients with complete or nearly complete hair loss must intake the pill with a quantity of 4 mg/day to improve hair loss 

• In June 2022, Revian Inc., a subsidiary of KNOW Bio LLC, a medical technology innovator company, unveiled positive result regarding the use of Revian Red System for providing treatment assistance to patients with central centrifugal cicatricial alopecia (CCCA)

• In September 2021, Dr. Reddy’s Laboratories Ltd., a leading multinational pharmaceutical organization, introduced minoxidil, a prescription drug for the treatment of alopecia in men

Alopecia Market Report Scope

Global Alopecia Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global alopecia market report based on disease type, treatment, gender, sales channel, end-use, and region:

• Disease Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Alopecia Areata

    • Male

    • Female

  • Cicatricial Alopecia

    • Male

    • Female

  • Traction Alopecia

    • Male

    • Female

  • Alopecia Totalis

    • Male

    • Female

  • Alopecia Universalis

    • Male

    • Female

  • Androgenetic Alopecia

    • Male

    • Female

  • Others

    • Male

    • Female

• Treatment Outlook (Revenue, USD Million, 2018 - 2030)

  • Pharmaceuticals

    • Topical

      • OTC

        • Minoxidil

        • Others

      • Prescription

        • Betamethasone Dipropionate

        • Fluocinolone Acetonide

        • Finasteride

        • Minoxidil

    • Oral

    • OTC

    • Prescription

      • Minoxidil

      • Finasteride

      • Corticosteroids

      • Others (JAK inhibitors and others)

    • PRP

  • Devices

    • Laser Cap

    • Laser Comb

    • Laser Helmet

• Gender Outlook (Revenue, USD Million, 2018 - 2030)

  • Male

  • Female

• Sales Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Prescriptions

  • OTC

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Homecare Settings

  • Dermatology Clinics

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S

    • Canada

  • Europe

    • UK

    • Germany

    • Spain

    • France

    • Italy

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait